Loading...
•
Mar 31, 2023
Nuvectis Pharma Q1 2023 Earnings Report
NXP900 IND was cleared by the FDA.
Key Takeaways
Nuvectis Pharma announced that the FDA cleared the Investigational New Drug Application for NXP900, including the Phase 1 clinical trial protocol. Nuvectis now has two precision oncology, clinical-stage drug candidates, NXP800 and NXP900.
FDA cleared the Company's Investigational New Drug Application for NXP900.
Nuvectis has two precision oncology, clinical-stage drug candidates, NXP800 and NXP900.
NXP900 presents a unique opportunity due to its differentiated mechanism of action and pharmacologic attributes.
Phase 1a study for NXP900 is expected to commence in the coming months.
Forward Guidance
Nuvectis is focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology and is currently developing two drug candidates, NXP800 and NXP900.
Positive Outlook
- NXP800 is a clinical stage, oral small molecule currently in a Phase 1b study.
- NXP800 was granted Fast Track Designation by the FDA for the treatment of platinum-resistant, ARID1a-mutated, ovarian carcinoma.
- NXP900 is a novel inhibitor of SFKs with low nanomolar potency against YES1 and SRC.
- The IND for NXP900 has been cleared by the FDA.
- The Phase 1a study for NXP900 is expected to commence in the coming months.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...